Managing heartburn and GLP-1s

Chris Brooker 16/01/2026

The widespread uptake of glucagon-like peptide-1 (GLP-1) receptor agonists has brought a new wave of gastrointestinal complaints to the pharmacy counter In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists have redefined the management of metabolic disease, reshaping how healthcare professionals approach both type 2 diabetes and obesity. Initially indicated for diabetes, agents such as semaglutide,

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

This web site is intended for Australian pharmacy professionals and is not a substitute for independent professional advice. Information and interactions contained in this website are for information purposes only and are not intended to be used to diagnose, treat, cure or prevent any disease. Further the accuracy, currency and completeness of the information available on this web site cannot be guaranteed. APPco Pty Ltd, its affiliates and their respective servants and agents do not accept any liability for any injury, loss or damage incurred by use of or reliance on the information made available via or through ajp.com.au whether arising from negligence or otherwise.

Managing heartburn and GLP-1s

Previous The top 10

Next WA student secures ‘Wildcard’

MENU

ajp.com.au

Previous The top 10

Next WA student secures ‘Wildcard’

MENU

ajp.com.au

Tags

Hi there! 👋 Looks like you’re not logged in.